Profile picture

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)
Membership: FESC Member
Follow
Logo ESC

Contributor content

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial
Presentation
Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial
Read more
PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.
Presentation
PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.
Read more
Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of >143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada
Presentation
Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of >143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada
Read more
Clinical implications for post-ACS patients
Presentation
Clinical implications for post-ACS patients
Read more
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
Presentation
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
Read more
How might PCSK9 inhibition change this debate?
Presentation
How might PCSK9 inhibition change this debate?
Read more

ESC 365 is supported by

novartis Explore sponsored resources